首页> 美国卫生研究院文献>Experimental and Therapeutic Medicine >Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction
【2h】

Long-term statin use before primary percutaneous coronary intervention improves treatment outcomes of acute myocardial infarction

机译:在初级经皮冠状动脉介入治疗之前长期使用他汀类药物可改善急性心肌梗死的治疗效果

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Numerous studies have reported that high-dose statin loading therapy prior to primary percutaneous coronary intervention (PPCI) improves the clinical outcomes of patients following acute myocardial infarction (AMI). However, little is known about the effects of long-term statin use prior to PPCI on such outcomes. Therefore, the aim of the present analysis was to clarify the effects of long-term statin use before PPCI on the treatment outcomes of patients following AMI. The records of 213 patients who had AMI and met the inclusion criteria were retrospectively reviewed. Patients were divided into two groups: A control group (n=178) who had received no statin pretreatment before AMI onset, and a statin group (n=35) who had received statin treatment for ≥1 month before AMI onset. All patients received a standard treatment regimen for the secondary prevention of coronary artery disease after PPCI. Baseline clinical variables, details of the PPCI procedure and clinical outcomes within 3 months after treatment were reviewed. Patients in the statin group were significantly older than those in the control group (P=0.003). Compared with the control group, there was a greater proportion of patients with hyperlipidemia and previous angina pectoris in the statin group. There were no differences in the use of other drugs (aspirin, β-blockers and angiotensin-converting enzyme inhibitors) prior to PPCI between the two groups. The corrected TIMI frame count (cTFC) was significantly lower in the statin group than in the control group (24.1±12.8 vs. 29.4±14.3, respectively; P=0.043). Multivariable linear regression analysis showed that long-term statin use before AMI was a significant predictor of cTFC after PPCI (P=0.012). Furthermore, the incidence of major adverse cardiac events within 3 months after PPCI was higher in the control group than in the statin group (16.8 vs. 2.9%, respectively; P=0.032). Logistic regression analysis showed that previous statin use was associated with the incidence of major adverse cardiac events within 3 months after treatment (P=0.012). The results of the present study demonstrate that long-term statin use prior to PPCI improved treatment outcomes after AMI in actual clinical practice.
机译:大量研究报告称,在原发性经皮冠状动脉介入治疗(PPCI)之前进行大剂量他汀类药物负荷治疗可改善急性心肌梗死(AMI)患者的临床结局。但是,对于PPCI之前长期服用他汀类药物对此类结果的影响知之甚少。因此,本分析的目的是阐明在PPCI之前长期使用他汀类药物对AMI患者的治疗效果的影响。回顾性分析213例患有AMI并符合纳入标准的患者的记录。将患者分为两组:对照组(n = 178),在AMI发作前未接受他汀类药物的预处理;和他汀组(n = 35),在AMI发作前≥1个月接受他汀类药物的治疗。所有患者均接受了PPCI后二级预防冠心病的标准治疗方案。回顾了治疗后3个月内的基线临床变量,PPCI程序的详细信息和临床结局。他汀类药物组的患者明显比对照组大(P = 0.003)。与对照组相比,他汀类药物组中高脂血症和既往心绞痛患者的比例更高。两组之间在PPCI之前使用其他药物(阿司匹林,β受体阻滞剂和血管紧张素转化酶抑制剂)没有差异。他汀类药物组的校正TIMI帧计数(cTFC)显着低于对照组(分别为24.1±12.8和29.4±14.3; P = 0.043)。多变量线性回归分析显示,AMI前长期服用他汀类药物是PPCI后cTFC的重要预测指标(P = 0.012)。此外,对照组中PPCI后3个月内主要不良心脏事件的发生率高于他汀类药物组(分别为16.8和2.9%; P = 0.032)。 Logistic回归分析显示,以前使用他汀类药物与治疗后3个月内主要不良心脏事件的发生率相关(P = 0.012)。本研究的结果表明,在实际临床实践中,PPCI前长期服用他汀类药物可改善AMI后的治疗效果。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号